Needham Reiterates a Hold Rating on Avadel Pharmaceuticals (AVDL)

​Avadel Pharmaceuticals plc (NASDAQ:AVDL) is one of the Hottest Small Cap Stocks to Buy Now. On November 5, Ami Fadia from Needham reiterated a Hold rating on Avadel Pharmaceuticals plc (NASDAQ:AVDL) without disclosing any price target.

​The rating follows the company’s Q3 2025 results released on November 4. During the quarter, the company grew its revenue by 54.86% year-over-year to $77.47 million, surpassing analysts’ estimates by $3.89 million. However, the EPS of $0 fell short of the expectations by $0.05. Management attributed revenue growth to robust sales of LUMRYZ and a 48% increase to 3,400 patients on LUMRYZ as of September 30, 2025.

​Although Avadel Pharmaceuticals plc (NASDAQ:AVDL) missed EPS estimates, its net income of $20,000 for the quarter was significant. The net income reflected a significant improvement versus the same quarter previous year, where the company reported a net loss of $2.6 million, translating to a negative EPS of $0.03. This was aided by a reversal of $9.5 million by Jazz in conjunction with the Settlement Agreement.

​Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a biopharmaceutical company that develops extended-release drug formulations to improve patient treatment experiences. Their main product, LUMRYZ, is an FDA-approved once-at-bedtime extended-release sodium oxybate therapy for excessive daytime sleepiness in adults and children with narcolepsy.

While we acknowledge the potential of AVDL to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AVDL and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.